Quarterly report pursuant to Section 13 or 15(d)

Acquisitions - Narrative (Details)

v3.19.2
Acquisitions - Narrative (Details)
 3 Months Ended 6 Months Ended 39 Months Ended
Mar. 31, 2019
USD ($)
Sep. 25, 2018
shares
Sep. 24, 2018
USD ($)
therapy
milestone
$ / shares
shares
Feb. 16, 2018
USD ($)
Nov. 17, 2017
USD ($)
shares
Jun. 30, 2019
USD ($)
$ / shares
Jun. 30, 2018
USD ($)
Jun. 30, 2019
USD ($)
$ / shares
Jun. 30, 2018
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2018
USD ($)
$ / shares
Aug. 17, 2018
$ / shares
Business Acquisition [Line Items]                        
Common stock, par value (in dollars per share) | $ / shares     $ 0.001     $ 0.001   $ 0.001     $ 0.001 $ 0.001
Fair value of debt assumed           $ 0 $ (15,075,000) $ 0 $ (15,075,000)      
Goodwill           16,411,123   16,411,123     $ 16,411,123  
Impairment of intangible assets           1,449,121 1,701,875 1,449,121 1,701,875      
Impairment of intangible assets             1,900,000          
Inventory, net           617,609   617,609     1,110,780  
Avadel                        
Business Acquisition [Line Items]                        
Cash       $ 1                
Fair value of debt assumed       (15,075,000)                
Contingent consideration       7,900,000                
Goodwill       $ 3,778,001                
Goodwill tax deductible period       15 years                
Fair value assigned to intangible asset at purchase       $ 18,291,000                
Fair value of consideration transferred       1                
TRx                        
Business Acquisition [Line Items]                        
Cash         $ 18,900,000              
Contingent consideration           0   0     $ 0  
Goodwill         12,633,122              
Fair value assigned to intangible asset at purchase         $ 19,596,000              
Unregistered shares of common stock issued or issuable as part of acquisition (in shares) | shares         7,534,884              
Shares issued for purchase of business (in shares)         $ 8,514,419              
Shares issued upon closing (in shares) | shares         5,184,920              
Contingent shares issuable as part of acquisition (in shares) | shares         2,349,968              
Goodwill, expected tax deductible amount         $ 8,700,000              
Fair value of consideration transferred         28,781,052              
PAI Sales & Marketing Agreement | TRx                        
Business Acquisition [Line Items]                        
Fair value assigned to intangible asset at purchase         2,553,000              
Flexichamber                        
Business Acquisition [Line Items]                        
Inventory, net           0   0        
Change in inventory reserve           200,000   200,000        
Flexichamber | Developed Technology Rights | Avadel                        
Business Acquisition [Line Items]                        
Fair value assigned to intangible asset at purchase $ 1,400,000     1,677,000   0   0        
Impairment of intangible assets           $ 1,400,000   $ 1,400,000        
LiquiTime Process | In Process Research and Development | Avadel                        
Business Acquisition [Line Items]                        
Fair value assigned to intangible asset at purchase       $ 0                
Metafolin | Acquired product marketing rights | TRx                        
Business Acquisition [Line Items]                        
Fair value assigned to intangible asset at purchase         11,987,000              
Millipred | Acquired product marketing rights | TRx                        
Business Acquisition [Line Items]                        
Fair value assigned to intangible asset at purchase         5,056,000              
Ulesfia | Acquired product marketing rights | TRx                        
Business Acquisition [Line Items]                        
Fair value assigned to intangible asset at purchase         0              
Nonrecurring | Level 3 | PAI Sales & Marketing Agreement | TRx                        
Business Acquisition [Line Items]                        
Fair value of sales and marketing agreement             $ 0   $ 0      
Ichorion                        
Business Acquisition [Line Items]                        
Consideration issued (in shares) | shares   5,800,000 5,800,000                  
Contingent consideration     $ 15,000,000                  
Fair value of shares issued     20,000,000                  
Intangible assets     18,700,000                  
Cash acquired     $ 1,600,000                  
Number of preclinical therapies | therapy     3                  
Transaction costs     $ 200,000                  
Number of contingent consideration milestones | milestone     3                  
Milestone payment $ 0                      
Ichorion | Assembled Workforce                        
Business Acquisition [Line Items]                        
Intangible assets     $ 200,000                  
Useful life (in years)     2 years                  
Milestone Two | TRx                        
Business Acquisition [Line Items]                        
Contingent consideration         2,000,000              
Milestone Three | TRx                        
Business Acquisition [Line Items]                        
Contingent consideration         $ 2,000,000              
Forecast | Milestone One | Ichorion                        
Business Acquisition [Line Items]                        
Milestone payment                   $ 6,000,000    
Forecast | Milestone Two | Ichorion                        
Business Acquisition [Line Items]                        
Milestone payment                   5,000,000    
Forecast | Milestone Three | Ichorion                        
Business Acquisition [Line Items]                        
Milestone payment                   $ 4,000,000